| Literature DB >> 32893530 |
Shan-Shan Suo1,2,3, Chen-Ying Li1,2,3, Yi Zhang1,2,3, Jing-Han Wang1,2,3, Yin-Jun Lou1,2,3, Wen-Juan Yu1,2,3, Jie Jin1,2,3.
Abstract
Acute lymphocytic leukemia (ALL) is one of the most common malignancies, especially in young people. Combination chemotherapy for ALL typically includes corticosteroids (Kantarjian et al., 2000). Hyperglycemia is a well-recognized complication of corticosteroids, and chemotherapy-induced diabetes (CID) is not uncommon (27.5%-37.0%) during the treatment of ALL (Hsu et al., 2002; Weiser et al., 2004; Alves et al., 2007). Besides the effect of corticosteroids, potential factors triggering hyperglycemia in ALL also include direct infiltration of the pancreas by leukemia cells and β cell dysfunction induced by chemotherapeutic agents such as L-asparagine (Mohn et al., 2004).Entities:
Keywords: Acute lymphoblastic leukemia; Diabetes mellitus; Clinical characteristics
Mesh：
Substances：
Year: 2020 PMID： 32893530 PMCID： PMC7519633 DOI： 10.1631/jzus.B1900719
Source DB: PubMed Journal: J Zhejiang Univ Sci B ISSN： 1673-1581 Impact factor: 3.066